A5070962149- Ovarian cancer diagnosis and treatment
- Chromosomal and Genetic Variations
- Intraperitoneal and Appendiceal Malignancies
- Cancer Treatment and Pharmacology
- Endometrial and Cervical Cancer Treatments
- Lung Cancer Treatments and Mutations
- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Plant Virus Research Studies
- Cancer Genomics and Diagnostics
- Plant Disease Resistance and Genetics
- Genomics and Phylogenetic Studies
- Monoclonal and Polyclonal Antibodies Research
- BRCA gene mutations in cancer
- Plant Pathogens and Resistance
- Lung Cancer Research Studies
- Shoulder and Clavicle Injuries
- PARP inhibition in cancer therapy
- Cancer survivorship and care
- Gestational Trophoblastic Disease Studies
- Multiple and Secondary Primary Cancers
- CRISPR and Genetic Engineering
- Shoulder Injury and Treatment
- Analytical Chemistry and Chromatography
- Cancer therapeutics and mechanisms
Technische Universität Dresden
2008-2024
Schulthess-Klinik
2020-2024
University Medical Center Hamburg-Eppendorf
2024
Universität Hamburg
2024
Centre Hospitalier Universitaire de Besançon
2019
University of Freiburg
2017
Institut de Cancérologie de Lorraine
1998-2016
Centre Léon Bérard
2014-2016
Centre Antoine Lacassagne
2014-2016
Université Claude Bernard Lyon 1
2007-2016
In platinum-resistant ovarian cancer (OC), single-agent chemotherapy is standard. Bevacizumab active alone and in combination. AURELIA the first randomized phase III trial to our knowledge combining bevacizumab with OC.Eligible patients had measurable/assessable OC that progressed < 6 months after completing platinum-based therapy. Patients refractory disease, history of bowel obstruction, or > two prior anticancer regimens were ineligible. After investigators selected (pegylated liposomal...
Background: The combination of carboplatin and paclitaxel is the standard care for treatment ovarian cancer, yet rates recurrence death remain high. We performed a prospective randomized phase III study to examine whether sequential administration topotecan can improve efficacy in first-line advanced epithelial cancer. Methods: A total 1308 patients with previously untreated cancer (International Federation Gynecology Obstetrics stages IIB–IV) were randomly assigned receive six cycles...
Despite the progress that has been achieved, long-term survival rates in patients with advanced ovarian cancer are still disappointing. One attempt to improve results could be addition of non-cross-resistant drugs platinum-paclitaxel combination regimens. Anthracyclines were among candidates for incorporation as a third drug into first-line regimens.We performed prospectively randomized phase III study comparing carboplatin-paclitaxel (TC; area under curve 5/175 mg/m2, respectively)...
Despite a typically good response to first-line combination chemotherapy, the prognosis for patients with advanced ovarian cancer remains poor because of acquired chemoresistance. The use targeted therapies such as trastuzumab may potentially improve outcomes cancer. HER2 overexpression/amplification has been reported in cancer, but exact percentage HER2-positive tumors varies widely literature. In this study, gene status was evaluated large, multicentric series 320 including 243 enrolled...
LBA5002^ The full, final text of this abstract will be available at abstract.asco.org 12:01 AM (EDT) on Saturday, June 2, 2012, and in the Annual Meeting Proceedings online supplement to 20, issue Journal Clinical Oncology. Onsite Meeting, printed Saturday edition ASCO Daily News.
LBA5002^ Background: In three phase III trials in OC (2 front line, 1 PT-sensitive recurrent), BEV + CT → significantly improved progression-free survival (PFS) vs alone. AURELIA is the first randomized trial of PT-resistant OC. Methods: Eligible patients (pts) had (measurable by RECIST 1.0 or assessable) that progressed ≤6 mo after ≥4 cycles PT-based therapy. Pts with refractory OC, history bowel obstruction, >2 prior anticancer regimens were ineligible. After selection investigator...
Extrachromosomal circular DNAs (eccDNAs) are ring-like DNA structures physically separated from the chromosomes with 100 bp to several megabasepairs in size. Apart carrying tandemly repeated DNA, eccDNAs may also harbor extra copies of genes or recently activated transposable elements. As occur all eukaryotes investigated so far and likely play roles stress, cancer, aging, they have been prime targets recent research-with their investigation limited by scarcity computational tools.Here, we...
Abstract Although both are salient features of genomes, at first glance ribosomal DNAs and transposable elements genetic with not much in common: whereas mainly viewed as housekeeping genes that uphold all prime genome functions, generally portrayed selfish disruptive. These opposing characteristics also mirrored other attributes: organization tandem (ribosomal DNAs) versus a dispersed manner (transposable elements); evolution concerted by diversification activity prolongs genomic stability...
Trastuzumab plus chemotherapy has become the standard of care for human epidermal growth factor receptor-2 (HER-2) -positive breast cancer. Trastuzumab-based preoperative systemic therapy (PST; neoadjuvant therapy) also appears promising, warranting further investigation.Patients with HER-2-positive, stage II/III, noninflammatory, operable cancer requiring a mastectomy (but who wanted to conserve breast) received trastuzumab 4 mg/kg (day 1), followed by 2 weekly, docetaxel 75 mg/m2 every 3...
One attempt to improve long-term survival in patients with advanced ovarian cancer was thought be the addition of more non-cross-resistant drugs platinum-paclitaxel combination regimens. Gemcitabine among candidates for a third drug.We performed prospective, randomized, phase III, intergroup trial compare carboplatin plus paclitaxel (TC; area under curve [AUC] 5 and 175 mg/m(2), respectively) same additional gemcitabine 800 mg/m(2) on days 1 8 (TCG) previously untreated epithelial cancer. TC...
Purpose Volasertib is a potent and selective cell-cycle kinase inhibitor that induces mitotic arrest apoptosis by targeting Polo-like kinase. This phase II trial evaluated volasertib or single-agent chemotherapy in patients with platinum-resistant -refractory ovarian cancer who experienced failure after treatment two three therapy lines. Patients Methods were randomly assigned to receive either 300 mg intravenous infusion every 3 weeks an investigator’s choice of single-agent, nonplatinum,...